Treatment Outcomes

MRSA SCCmec Type

I

II

III

IV, PVL–

IV, PVL+

Days, Mean (SE)

Linezolid

Length of IV therapy^ab

(N = 25)

6.4 (0.89)^*

(N = 28)

5.7 (0.80)^*

(N = 13)

7.9 (0.96)^*

(N = 20)

6.3 (0.94)^*

(N = 72)

4.0 (0.33)

Length of IV therapy (All)

(N = 25)

6.4 (0.89)^*

(N = 50)

3.2 (0.60)^*

(N = 15)

6.9 (1.09)^*

(N = 38)

3.3 (0.71)^*

(N = 142)

2.0 (0.24)

Length of stay^a

(N = 24)

10.8 (1.39)^*

(N = 27)

8.2 (0.97)^*

(N = 13)

12.7 (1.87)^*

(N = 20)

13.6 (1.53)^*

(N = 71)

5.8 (0.60)

Length of stay (All)

(N = 25)

10.9 (1.34)^*

(N = 50)

7.6 (0.76)^*

(N = 15)

12.3 (1.86)^*

(N = 38)

13.7 (1.11)^*

(N = 142)

4.4 (0.40)

Vancomycin

Length of IV therapy

(N = 23)

12.0 (0.86)^*

(N = 38)

10.6 (0.64)

(N = 18)

10.8 (0.82)

(N = 43)

9.3 (0.48)

(N = 153)

9.4 (0.31)

Length of stay

12.6 (1.33)^*

9.1 (1.05)^*

12.8 (1.39)^*

14.3 (1.06)^*

5.6 (0.42)